Clinical Trials Browser

Phase 1/2 × Active not recruiting × Carboplatin × Clear all

NCT01386385 2026-05-26

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 1/2 Active not recruiting

53 enrolled 21 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1/2 Active not recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT04083599 2026-05-06

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Phase 1/2 Active not recruiting

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04331067 2026-05-06

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Phase 1/2 Active not recruiting

15 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT04663347 2026-05-05

EPCORE™ NHL-2

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05083481 2026-05-05

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT03393884 2026-05-04

OVATION 2

Phase 1/2 Active not recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06477523 2026-04-29

Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC

Phase 1/2 Active not recruiting

SCLC, Extensive Stage

NCT05108870 2026-04-24

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

Phase 1/2 Active not recruiting

Head and Neck Neoplasms

NCT04216316 2026-04-13

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

12 enrolled 25 charts

Lung Neoplasms

NCT04528680 2026-04-13

SC9/ABX

Phase 1/2 Active not recruiting

Glioblastoma, Gliosarcoma

NCT06624059 2026-04-08

HORIZON 2

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04938583 2026-04-06

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Phase 1/2 Active not recruiting

Ovarian Neoplasms

NCT03473743 2026-03-30

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Phase 1/2 Active not recruiting

125 enrolled 19 charts

Carcinoma, Transitional Cell

NCT05142696 2026-03-17

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Phase 1/2 Active not recruiting

Extensive Stage Small Cell Lung Cancer

NCT05229497 2026-03-09

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

Phase 1/2 Active not recruiting

Advanced Malignant Tumors

NCT05904379 2026-03-09

AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

Advanced Non-small-cell Lung Cancer

NCT03781986 2026-03-03

APG-115 in Salivary Gland Cancer Trial

Phase 1/2 Active not recruiting

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT04644068 2026-02-19

PETRA

Phase 1/2 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Solid Cancer

NCT02726997 2025-12-18

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Phase 1/2 Active not recruiting

Fallopian Tube Neoplasms

NCT04728230 2025-12-18

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

Phase 1/2 Active not recruiting

Lung Neoplasms

NCT03616886 2024-12-19

SYNERGY

Phase 1/2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04652076 2024-10-08

GYNET

Phase 1/2 Active not recruiting

Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT02628405 2024-07-01

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

Phase 1/2 Active not recruiting

30 enrolled 15 charts

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03544736 2023-03-22

Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)

Phase 1/2 Active not recruiting

Gastrointestinal

Esophageal Neoplasms

NCT03064867 2022-11-16

Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1/2 Active not recruiting

Dendritic Cell Sarcoma, Interdigitating